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• Recalcitrant infections of bone and soft tissue are 
commonly encountered by orthopaedic surgeons. 
• Treatment strategies include long-term antibiotic 
administration for suppression and/or surgical 
debridement to obtain source control.1 
• Intraoperatively identifying living, viable bone can be 
challenging.
• Debridement to bleeding bone may not correlate with a 
bone’s metabolic state.8-10 
• Living bone is known to contain fluorophores (Tryptophan,
Tyrosine, Phenylalanine), which enable it to naturally
fluoresce.5,6 
• Bone Fluorescence is also achieved via the chelation of 
tetracycline molecules within the inorganic mineral matrix 
of bone.3,4 
• The quantity of healthy osteocytes correlates with visible 
fluorescence. Thus, fluorescence can be used to
demarcate viable bone.11-13 
• A form of this technique was originally described in 2002
and has not been presented since that time.2 
Surgical Technique: 
• Pre-op use of tetracycline allowing enough time for the
metabolite to be incorporated into live bone. 
• Doxycycline dosing can range from an IV formulation of 
100 mg delivered in pre-op holding to a multi-week 
regimen in an oral formulation of 100 mg BID. 
• OR lights turned off and a non-sterile team member uses 
a blacklight to illuminate the surgical field. 
• The intensity of fluorescence will be in stark contrast to 
any non-viable areas of bone. 
• Operations including ORIF, IM nailing, placement of 
antibiotic-laden cement/beads into a bone defect to stage
for an additional procedure (i.e. Masquelet), can be done 
per clinical scenario. 
Case Series: 
• Intraoperative sample photos are included depicting
bone fluorescence. 
• Figure 1: 
A) Intraoperative fluorescence of tibia noted pre-debridement. 
B) More complete fluorescence of the same tibia noted following
completion of debridement. 
• Figure 2: 
Demonstrated is a live, viable tibia with bone fluorescence noted 
intraoperatively. This patient had not received any preoperative
doxycycline. 
Case Series Continued: 
• Figure 3: 
Specimen of fresh-frozen cadaveric humerus with blacklight 
exposure. Notice that minimal to no fluorescence is 
exhibited by non-viable, dead bone. 
Case Example: 30 YO F 
• PMH: Recurrent skin abscesses. 
• Presented in 2018 with vague leg pain. 
• CT and MRI findings consistent with chroni 
osteomyelitis and intramedullary abscess of the
tibia. 
• Taken to the OR for I&D and cultures, which grew 
MRSA. 
• 5 days later, taken back to the OR for  
gentamicin/vancomycin-coated intramedullary nail 
and gentamicin/vancomycin-impregnated cement 
placement. 
• She was discharged on IV daptomycin and PO 
doxycycline 100mg BID. 
• 7 weeks later returned for repeat I&D with bone 
grafting of her tibia. 
• Intraoperatively, OR lights were shut off and a 
black light was used to illuminate the wound. 
• All exposed bone fluoresced, indicating live bone 
with no need for further debridement or resection. 
• At 1 year follow up, there was no tenderness over 
the tibia with full ROM and no complaints.   
Discussion: 
• The senior author of this manuscript prefers 
preoperative administration of 100 mg BID 
doxycycline for at least 1 month combined with the 
usage of an ordinary blacklight as the intraoperative 
excitation source. 
• The use of an ordinary blacklight is cost-effective, 
readily attainable, and proven to be efficacious.7 
• A ilmitation of the work is that lack of quantitative 
fluorescence measurements. It is hoped that any 
curious surgeon merely gives this technical trick an 
opportunity to demonstrate its worth. 
• More formal trials to objectively quantify 
fluorescence intensity should follow. 
Conclusion: 
• The present manuscript has revived the concept of 
fluorescence-guided bone debridement based 
upon the biochemistry of bone labelling by 
tetracyclines. 
• Preoperative administration of doxycycline in a 
patient with osteomyelitis may allow for increased 
efficacy in guiding the surgical debridement 
procedures. 
• Variations in the technique do exist and can 
function quite well, however the concept of bone 
labelling for fluorescent-guided resection of chronic 
osteomyelitis can be a useful tool in these 
challenging cases. 
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